Literature DB >> 6339966

Extracapillary glomerulonephritis with necrotizing vasculitis in D-penicillamine-treated rheumatoid arthritis.

G Banfi, E Imbasciati, L Guerra, M J Mihatsch, C Ponticelli.   

Abstract

Rapidly progressive glomerulonephritis occurred in a woman with rheumatoid arthritis (RA) who had been treated with D-penicillamine for 3 months. Light microscopy study of the kidney showed severe glomerulonephritis with crescent formation in 50% of glomeruli and necrotizing vasculitis. Immunoflurescence revealed IgA and C3 granular deposits diffusely distributed along the capillary walls. The patient was treated with steroid 'pulse', antiplatelet agents and heparin and a partial recovery of renal function was observed after 2 months of anuria. This renal picture is unlike that reported in RA and a causative role for D-penicillamine is suggested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339966     DOI: 10.1159/000182906

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis.

Authors:  G Frampton; D R Jayne; G J Perry; C M Lockwood; J S Cameron
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Progressive proliferative glomerulonephritis in a patient with rheumatoid arthritis treated with D-penicillamine.

Authors:  A J Williams; J N Fordham; C G Barnes; F J Goodwin
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

4.  D-penicillamine-induced glomerulonephritis with crescent formation: Remission following drug discontinuation.

Authors:  S Mokuda; M Onishi; K Takasugi
Journal:  Indian J Nephrol       Date:  2013-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.